AbbVie Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

FY2026 EPS Estimates for AbbVie Cut by Erste Group Bank

📉 Erste Group Bank analyst H. Engel cut FY2026 EPS estimates for AbbVie to $14.08 from $14.23, placing the forecast below the consensus of $14.16.

📊 The stock opened at $254.53 with a market cap of $449.70 billion and a PE ratio of 125.38, trading above its key moving averages.

🚀 Q1 earnings beat consensus significantly with $2.65 EPS versus $2.59 expected and revenue reaching $15 billion, up 12.4% year-over-year.

📈 Major institutional investors including Calamos Advisors and Wealth Enhancement Advisory Services increased their holdings by over 3% in the fourth quarter.

💰 AbbVie declared a quarterly dividend of $1.73 per share with an ex-dividend date of July 15th, offering a 2.7% annualized yield.

🏆 Analyst sentiment remains mixed but generally positive, with HSBC setting a $300 price target and Guggenheim raising its objective to $261.

🧬 The company continues to expand its portfolio in immunology, oncology, neuroscience, virology, and women's health therapeutic areas.

📉 Wall Street Zen downgraded the stock from 'strong-buy' to 'buy', while Sanford C. Bernstein maintained a 'market perform' rating.

Bullish Signals
  • AbbVie reported Q1 revenue of $15 billion, surpassing analyst estimates of $14.72 billion and showing a robust 12.4% year-over-year growth.
  • The company beat Q1 earnings expectations with EPS of $2.65 compared to the consensus of $2.59, demonstrating strong operational performance.
  • Multiple major institutional investors increased their stakes in the fourth quarter, including Calamos Advisors raising holdings by 3.4% and Wealth Enhancement Advisory Services by 11.7%.
  • HSBC issued a high price objective of $300.00 for AbbVie shares, indicating strong long-term confidence from major financial institutions.
  • The stock trades above both its 50-day moving average ($229.80) and 200-day moving average ($221.94), suggesting positive short-to-medium term momentum.
  • AbbVie maintains a high institutional ownership of 70.23%, reflecting strong confidence from professional money managers in the company's future prospects.
Risk Factors
  • Erste Group Bank analyst H. Engel lowered its FY2026 EPS forecast to $14.08, which is below the current market consensus estimate of $14.16.
  • Wall Street Zen downgraded AbbVie from a 'strong-buy' rating to a 'buy' rating, indicating a reduction in immediate bullish sentiment.
  • The stock carries a very high PE ratio of 125.38, which may suggest the market is pricing in significant future growth that could be difficult to sustain.
Full Analysis
Analyst H. Engel at Erste Group Bank lowered its full-year 2026 earnings per share (EPS) estimate for AbbVie to $14.08, down from a previous forecast of $14.23. This adjustment brings the analyst's projection slightly below the current market consensus of $14.16. The report was issued on July 15th, contributing to a mixed landscape of Wall Street sentiment regarding the biopharmaceutical giant. Despite the downgrade from Erste Group, AbbVie maintains a 'Moderate Buy' average rating with an average price target of $267.67 according to MarketBeat data. The stock recently opened at $254.53, trading above its 50-day and 200-day moving averages. Recent analyst actions include Citigroup raising its price target to $260.00 with a neutral rating, while HSBC set a higher objective of $300.00. The company reported strong first-quarter results on April 29th, beating consensus estimates with EPS of $2.65 and revenue of $15 billion, which represented a 12.4% year-over-year increase. Institutional ownership remains high at 70.23%, with several major firms like Calamos Advisors and Wealth Enhancement Advisory Services increasing their stakes in the fourth quarter. AbbVie declared a quarterly dividend of $1.73 per share, payable on August 14th to shareholders of record as of July 15th. This represents an annualized yield of 2.7% based on a payout ratio of 340.89%. The company continues to focus on its diverse portfolio across immunology, oncology, and neuroscience, maintaining its position as a global research-driven biopharmaceutical entity.